Antiemetics in hematopoietic cell transplantation:
an overview of randomized trials
DOI:
https://doi.org/10.46765/2675-374X.2023v4n2p187Keywords:
Antiemetics, Hematopoietic cell transplnatation, High-dose chemotherapy, Total body irradiationAbstract
Antiemetics play a key role in hematopoietic cell transplantation (HCT). High-dose chemotherapy and total body irradiation (TBI) have a high emetogenic potential, and vomiting and nausea during conditioning regimen and thereafter impair oral intake, which can lead to weight loss, hyperglycemia due to parenteral nutrition, infectious disease, and increased transplant-related mortality. We searched for randomized trials on antiemetics in HCT. Triplet prophylaxis with a 5-HT antagonist, an NK-1 antagonist, and dexamethasone is a common practice in hematopoietic cell transplantation. Prophylaxis is usually given during the conditioning regimen and sometimes up to a few days later. NK-1 antagonist usage is supported by randomized trials. Olanzapine reduces nauseas, based on a randomized trial. Although recommended by the ASCO guideline, the use of dexamethasone should be considered controversial given the higher incidence of adverse events with this medication in a randomized study and given a possible higher risk of infections, and therefore dexamethasone should be used with caution as an antiemetic in hematopoietic cell transplantation. Metoclopramide, diphenhydramine, and lorazepam are other drugs that also have antiemetic activity, have been used in HCT, and can be used in selected cases.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
License and Copyright Policy
The Journal of Bone Marrow Transplantation and Cellular Therapy (JBMTCT) adopts an open access policy, ensuring that all published articles are freely available to the public without restrictions.
-
License
- All articles published in JBMTCT are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0).
- This license permits anyone to:
- Share: Copy and redistribute the material in any medium or format.
- Adapt: Remix, transform, and build upon the material for any purpose, even commercially.
- The only requirement is that appropriate credit is given to the original authors and source, a link to the license is provided, and any changes made are indicated.
More information about the license can be found here: Creative Commons Attribution 4.0 International License.
-
Authors’ Rights
- Authors retain the copyright to their work.
- Authors grant JBMTCT the right to publish the work and make it openly accessible online.
- Authors are free to:
- Distribute the published version of their article (e.g., post it on personal websites or institutional repositories).
- Use the article in future works, presentations, or derivative publications, as long as the original publication in JBMTCT is properly acknowledged.
-
No Embargo
- There is no embargo period; articles are made freely available immediately upon publication.
-
Ethical Use
- Users of JBMTCT articles must ensure proper citation of the authors and the journal.
- Articles must not be used in ways that violate ethical or legal standards.
-
Disclaimer
- While JBMTCT aims to ensure the accuracy and reliability of published content, the journal and its editors are not responsible for the consequences of its use.
For any questions regarding our licensing terms, please contact us at: journalbmtct@sbtmo.org.br
JBMTCT is committed to the principles of open access to advance knowledge and scientific collaboration.
